AUTHOR=Meng Yu , Quan Quan , Zhang Fenfen , Liu Yao , Ren Siling , Mu Xiaoling 

TITLE=Prognostic Value of Ki-67 Index in Patients With Endometrial Stromal Sarcoma

JOURNAL=Frontiers in Medicine

VOLUME=Volume 8 - 2021

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.823505

DOI=10.3389/fmed.2021.823505

ISSN=2296-858X

ABSTRACT=Objective Ki-67 index is used to evaluate cell proliferation activity, which is related to tumor progression, metastasis and prognosis. We aimed to explore the optimal cut-off value of Ki-67 index for predicting recurrent endometrial stromal sarcoma, and to explore the prognostic value of Ki-67 index in endometrial stromal sarcoma.
Methods: A total of 82 patients with endometrial stromal sarcoma who were treated in our hospital were collected. Clinicopathological data of these patients were retrospectively analyzed. Ki-67 index was detected by the immunohistochemical method. Receiver operating characteristic curve and the Youden index were performed to determine the optimal cut-off value of Ki-67 index for predicting recurrent endometrial stromal sarcoma. The Cox regression was performed to analyze risk factors affecting prognosis of endometrial stromal sarcoma. The Kaplan–Meier method and Log-rank test were performed to analyze the survival of patients.
Results: The optimal cut-off value of Ki-67 index for predicting recurrent endometrial stromal sarcoma was 35%. The results of univariate analysis showed that high Ki-67 index (≥ 35%) was statistical significantly bound up with shorter progress free survival and overall survival. The results of multivariate analysis showed that Ki-67 index (P= 0.001) and ovarian preservation (P=0.040) were independent prognostic factors of progress free survival.
Conclusions: A Ki-67 index cut off of 35% was optimal for predicting recurrent endometrial stromal sarcoma. Ki-67 index may be a useful predictive and prognostic marker in endometrial stromal sarcoma.